Skip to main content
PMC home page
Thorax logoLink to Thorax
. 1998 May;53(5):363–367. doi: 10.1136/thx.53.5.363

How long should Atrovent be given in acute asthma?

C Brophy 1, B Ahmed 1, S Bayston 1, A Arnold 1, D McGivern 1, M Greenstone 1
PMCID: PMC1745211  PMID: 9708227

Abstract

BACKGROUND—In acute asthma the optimal duration of treatment with combination β agonist and anticholinergic nebuliser solutions is unknown; most studies have investigated single doses or treatment for up to 12 hours. To determine whether longer treatment with ipratropium bromide might aid recovery a study was undertaken in 106 patients with acute asthma.
METHODS—A double blind, randomised, placebo controlled, three group study was performed with all patients receiving ipratropium for 12 hours and salbutamol for 60 hours after admission (both nebulised four hourly), systemic steroids and, if necessary, theophylline. At 12 hours ipratropium was stopped in group I (n = 35) but was continued in the other two groups, and at 36 hours ipratropium was also stopped in group II (n = 35) while patients in group III (n = 36) continued with ipratropium for 60 hours. Spirometric tests were performed before and after salbutamol, and again 30and 60 minutes after ipratropium or placebo at 12, 36 and 60 hours. Peak flow rates (PEFR) were measured before and after each nebulisation.
RESULTS—There were no differences between the groups in PEFR on admission (group I: 214 l/min, group II: 198 l/min, group III: 221 l/min), or mean forced expiratory volume in one second (FEV1) at 12 hours (group I: 1.8 l, group II: 2.0 l, group III: 2.2 l), 36 hours (group I: 2.1 l, group II: 2.3 l, group III: 2.4 l), or at 60 hours (group I: 2.2 l, group II: 2.3 l, group III 2.5 l). Despite this, median time to discharge was significantly higher for patients in group I (5.4 days) than for those in groups II (4.1 days) and III (4.0days).
CONCLUSIONS—Combination nebulised therapy can be continued beyond 12 hours and up to 36 hours after admission with improved recovery time. Lung function testing may not reflect the full benefit of treatment.



Full Text

The Full Text of this article is available as a PDF (132.3 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bryant D. H. Nebulized ipratropium bromide in the treatment of acute asthma. Chest. 1985 Jul;88(1):24–29. doi: 10.1378/chest.88.1.24. [DOI] [PubMed] [Google Scholar]
  2. Bryant D. H., Rogers P. Effects of ipratropium bromide nebulizer solution with and without preservatives in the treatment of acute and stable asthma. Chest. 1992 Sep;102(3):742–747. doi: 10.1378/chest.102.3.742. [DOI] [PubMed] [Google Scholar]
  3. Higgins R. M., Stradling J. R., Lane D. J. Should ipratropium bromide be added to beta-agonists in treatment of acute severe asthma? Chest. 1988 Oct;94(4):718–722. doi: 10.1378/chest.94.4.718. [DOI] [PubMed] [Google Scholar]
  4. Karpel J. P., Schacter E. N., Fanta C., Levey D., Spiro P., Aldrich T., Menjoge S. S., Witek T. J. A comparison of ipratropium and albuterol vs albuterol alone for the treatment of acute asthma. Chest. 1996 Sep;110(3):611–616. doi: 10.1378/chest.110.3.611. [DOI] [PubMed] [Google Scholar]
  5. Leahy B. C., Gomm S. A., Allen S. C. Comparison of nebulized salbutamol with nebulized ipratropium bromide in acute asthma. Br J Dis Chest. 1983 Apr;77(2):159–163. doi: 10.1016/0007-0971(83)90022-0. [DOI] [PubMed] [Google Scholar]
  6. Lee P. C., Helsmoortel C. M., Cohn S. M., Fink M. P. Are low tidal volumes safe? Chest. 1990 Feb;97(2):430–434. doi: 10.1378/chest.97.2.430. [DOI] [PubMed] [Google Scholar]
  7. Louw S. J., Goldin J. G., Isaacs S. Relative efficacy of nebulised ipratropium bromide and fenoterol in acute severe asthma. S Afr Med J. 1990 Jan 6;77(1):24–26. [PubMed] [Google Scholar]
  8. O'Driscoll B. R., Taylor R. J., Horsley M. G., Chambers D. K., Bernstein A. Nebulised salbutamol with and without ipratropium bromide in acute airflow obstruction. Lancet. 1989 Jun 24;1(8652):1418–1420. doi: 10.1016/s0140-6736(89)90126-8. [DOI] [PubMed] [Google Scholar]
  9. Rebuck A. S., Chapman K. R., Abboud R., Pare P. D., Kreisman H., Wolkove N., Vickerson F. Nebulized anticholinergic and sympathomimetic treatment of asthma and chronic obstructive airways disease in the emergency room. Am J Med. 1987 Jan;82(1):59–64. doi: 10.1016/0002-9343(87)90378-0. [DOI] [PubMed] [Google Scholar]
  10. Teale C., Morrison J. F., Muers M. F., Pearson S. B. Response to nebulized ipratropium bromide and terbutaline in acute severe asthma. Respir Med. 1992 May;86(3):215–218. doi: 10.1016/s0954-6111(06)80058-2. [DOI] [PubMed] [Google Scholar]
  11. Ward M. J., Fentem P. H., Smith W. H., Davies D. Ipratropium bromide in acute asthma. Br Med J (Clin Res Ed) 1981 Feb 21;282(6264):598–600. doi: 10.1136/bmj.282.6264.598. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Thorax are provided here courtesy of BMJ Publishing Group

RESOURCES